Company Description
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer.
Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors.
The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell.
Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
| Country | Ontario, Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
Contact Details
Address: 2 Bloor St W., 7th Floor Toronto, A6 M4W 3E2 Ontario, Canada | |
| Phone | 416 648-5555 |
Stock Details
| Ticker Symbol | MDNAF |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001807983 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Fahar Merchant | Founder, Chairman, Chief Executive Officer and Pres |
| Rosemina Merchant | Founder, Chief Development Officer and Director |
| Elizabeth Williams C.A., CPA, CPA, CA | Chief Financial Officer and Corporate Secretary |
| Dr. John H. Sampson M.D., Ph.D., MBA | Chief Clinical Advisor |
| Dr. Martin Bexon M.D. | Head of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | AW | Amendment Withdrawal Request |
| Apr 16, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 16, 2024 | F-3/A | Filing |
| Apr 16, 2024 | F-10POS | Filing |
| Apr 10, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | 6-K | Report of foreign issuer |
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Mar 6, 2024 | 6-K | Report of foreign issuer |
| Feb 21, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | 6-K | Report of foreign issuer |